Literature DB >> 23203961

Nampt secreted from cardiomyocytes promotes development of cardiac hypertrophy and adverse ventricular remodeling.

Vinodkumar B Pillai1, Nagalingam R Sundaresan, Gene Kim, Sadhana Samant, Liliana Moreno-Vinasco, Joe G N Garcia, Mahesh P Gupta.   

Abstract

Nicotinamide phosphoribosyltransferase (Nampt) is an important coenzyme involved in cellular redox reactions. Inside the cell, Nampt (iNampt) functions as a rate-limiting enzyme in the NAD salvage pathway, and outside the cell (eNampt), it acts as a proinflammatory cytokine. High-circulating levels of Nampt are reported in different pathological conditions. This study was designed to examine the role of Nampt in the development of cardiac hypertrophy and ventricular remodeling. We studied the hypertrophic response in Nampt heterozygous (+/-) knockout and cardiac-specific overexpressing Nampt transgenic mice. Whereas Nampt(+/-) mice were protected against agonist (isoproterenol and angiotensin II)-induced hypertrophy, Nampt transgenic mice spontaneously developed cardiac hypertrophy at 6 mo of age. Experiments conducted to gain insight into the mechanism revealed that treatment of cardiomyocytes with recombinant (eNampt) or overexpression with Nampt-synthesizing adenovirus vector (Ad.Nampt) induced cardiomyocyte hypertrophy. The prohypertrophic effects of eNampt and Ad.Nampt were blocked by the addition of a Nampt-blocking antibody into cultures, thus suggesting that Nampt was in fact invoking hypertrophic response of cardiomyocytes by acting on the cell surface receptors. We also found increased Nampt levels in the supernatant of cardiomyocyte cultures subjected to stress by either serum starvation or H(2)O(2) treatment. Exploration of signaling pathways in Nampt-induced cardiac hypertrophy and fibrosis revealed increased activation of mitogen-activated protein kinases, namely, JNK1, p38, and ERK. This was also associated with increased calcineurin levels and nuclear factor of activated T-cell localization into the nucleus. From these studies we conclude that cardiomyocytes are capable of secreting Nampt during stress, and exogenous Nampt is a positive regulator of cardiac hypertrophy and adverse ventricular remodeling.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23203961      PMCID: PMC3774498          DOI: 10.1152/ajpheart.00468.2012

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  41 in total

1.  Akt1 is required for physiological cardiac growth.

Authors:  Brian DeBosch; Iya Treskov; Traian S Lupu; Carla Weinheimer; Attila Kovacs; Michael Courtois; Anthony J Muslin
Journal:  Circulation       Date:  2006-04-24       Impact factor: 29.690

Review 2.  Matrix metalloproteinases as markers of adverse remodeling after myocardial infarction.

Authors:  Bodh I Jugdutt
Journal:  J Card Fail       Date:  2006-02       Impact factor: 5.712

3.  Targeted disruption of gp130, a common signal transducer for the interleukin 6 family of cytokines, leads to myocardial and hematological disorders.

Authors:  K Yoshida; T Taga; M Saito; S Suematsu; A Kumanogoh; T Tanaka; H Fujiwara; M Hirata; T Yamagami; T Nakahata; T Hirabayashi; Y Yoneda; K Tanaka; W Z Wang; C Mori; K Shiota; N Yoshida; T Kishimoto
Journal:  Proc Natl Acad Sci U S A       Date:  1996-01-09       Impact factor: 11.205

Review 4.  White adipose tissue and cardiovascular disease.

Authors:  Yuji Matsuzawa
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2005-12       Impact factor: 4.690

5.  Adipocytokines and proinflammatory mediators from abdominal and epicardial adipose tissue in patients with coronary artery disease.

Authors:  K-H Cheng; C-S Chu; K-T Lee; T-H Lin; C-C Hsieh; C-C Chiu; W-C Voon; S-H Sheu; W-T Lai
Journal:  Int J Obes (Lond)       Date:  2007-09-18       Impact factor: 5.095

Review 6.  The secret life of NAD+: an old metabolite controlling new metabolic signaling pathways.

Authors:  Riekelt H Houtkooper; Carles Cantó; Ronald J Wanders; Johan Auwerx
Journal:  Endocr Rev       Date:  2009-12-09       Impact factor: 19.871

7.  Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure.

Authors:  Ichiro Shiojima; Kaori Sato; Yasuhiro Izumiya; Stephan Schiekofer; Masahiro Ito; Ronglih Liao; Wilson S Colucci; Kenneth Walsh
Journal:  J Clin Invest       Date:  2005-08       Impact factor: 14.808

8.  Visfatin/Pre-B cell colony-enhancing factor in amniotic fluid in normal pregnancy, spontaneous labor at term, preterm labor and prelabor rupture of membranes: an association with subclinical intrauterine infection in preterm parturition.

Authors:  Shali Mazaki-Tovi; Roberto Romero; Juan Pedro Kusanovic; Offer Erez; Francesca Gotsch; Pooja Mittal; Nandor Gabor Than; Chia-Lang Nhan-Chang; Neil Hamill; Edi Vaisbuch; Tinnakorn Chaiworapongsa; Samuel S Edwin; Jyh Kae Nien; Ricardo Gomez; Jimmy Espinoza; Claire Kendal-Wright; Sonia S Hassan; Gillian Bryant-Greenwood
Journal:  J Perinat Med       Date:  2008       Impact factor: 1.901

9.  Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor.

Authors:  B Samal; Y Sun; G Stearns; C Xie; S Suggs; I McNiece
Journal:  Mol Cell Biol       Date:  1994-02       Impact factor: 4.272

Review 10.  Cardiac remodeling in obesity.

Authors:  E Dale Abel; Sheldon E Litwin; Gary Sweeney
Journal:  Physiol Rev       Date:  2008-04       Impact factor: 37.312

View more
  29 in total

Review 1.  The importance of NAMPT/NAD/SIRT1 in the systemic regulation of metabolism and ageing.

Authors:  S Imai; J Yoshino
Journal:  Diabetes Obes Metab       Date:  2013-09       Impact factor: 6.577

Review 2.  Therapeutic Potential of NAD-Boosting Molecules: The In Vivo Evidence.

Authors:  Luis Rajman; Karolina Chwalek; David A Sinclair
Journal:  Cell Metab       Date:  2018-03-06       Impact factor: 27.287

3.  Impact of caloric restriction on myocardial ischaemia/reperfusion injury and new therapeutic options to mimic its effects.

Authors:  Susanne Rohrbach; Muhammad Aslam; Bernd Niemann; Rainer Schulz
Journal:  Br J Pharmacol       Date:  2014-06       Impact factor: 8.739

Review 4.  Nicotinamide phosphoribosyltransferase in malignancy: a review.

Authors:  Rodney E Shackelford; Kim Mayhall; Nicole M Maxwell; Emad Kandil; Domenico Coppola
Journal:  Genes Cancer       Date:  2013-11

Review 5.  The function of nicotinamide phosphoribosyltransferase in the heart.

Authors:  Chiao-Po Hsu; Takanobu Yamamoto; Shinichi Oka; Junichi Sadoshima
Journal:  DNA Repair (Amst)       Date:  2014-09-29

Review 6.  Angiotensin II Signal Transduction: An Update on Mechanisms of Physiology and Pathophysiology.

Authors:  Steven J Forrester; George W Booz; Curt D Sigmund; Thomas M Coffman; Tatsuo Kawai; Victor Rizzo; Rosario Scalia; Satoru Eguchi
Journal:  Physiol Rev       Date:  2018-07-01       Impact factor: 37.312

7.  Nicotinamide phosphoribosyltransferase inhibitor is a novel therapeutic candidate in murine models of inflammatory lung injury.

Authors:  Liliana Moreno-Vinasco; Hector Quijada; Saad Sammani; Jessica Siegler; Eleftheria Letsiou; Ryan Deaton; Laleh Saadat; Rafe S Zaidi; Joe Messana; Peter H Gann; Roberto F Machado; Wenli Ma; Sara M Camp; Ting Wang; Joe G N Garcia
Journal:  Am J Respir Cell Mol Biol       Date:  2014-08       Impact factor: 6.914

Review 8.  Sirtuin regulation in aging and injury.

Authors:  Ninu Poulose; Raghavan Raju
Journal:  Biochim Biophys Acta       Date:  2015-08-21

9.  Deficiency of cardiomyocyte-specific microRNA-378 contributes to the development of cardiac fibrosis involving a transforming growth factor β (TGFβ1)-dependent paracrine mechanism.

Authors:  Raghu S Nagalingam; Nagalingam R Sundaresan; Mariam Noor; Mahesh P Gupta; R John Solaro; Madhu Gupta
Journal:  J Biol Chem       Date:  2014-08-07       Impact factor: 5.157

Review 10.  Physiological and pathophysiological roles of NAMPT and NAD metabolism.

Authors:  Antje Garten; Susanne Schuster; Melanie Penke; Theresa Gorski; Tommaso de Giorgis; Wieland Kiess
Journal:  Nat Rev Endocrinol       Date:  2015-07-28       Impact factor: 43.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.